news
China approves IND application for Everest Medicines novel BTK inhibitor
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
List view / Grid view
Therapeutics
news
New antibiotic could stop advance of resistant pathogens
Using computational screening, researchers have discovered an antibiotic called Dynobactin, that halts the advance of antibiotic-resistant bacteria.
news
Protein-based therapy shows promise for individuals with ALS
In a petri dish under an environmental condition reminiscent of ALS, the team found that the protein activates a unique pathway inside cells that increases survival and protects endothelial cells from toxic substances in the blood.
news
Silo Pharma initiates pre-IND package for ketamine to treat fibromyalgia
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
news
FDA accepts IND application for Clarametyx antibody therapy CMTX-101
Clarametyx says the FDA has accepted an IND application for first-in-human trials of CMTX-101, an antibody to treat bacterial pneumonia.
article
Drug Target Review’s highlights from ELRIG Drug Discovery 2022
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
news
New study highlights how to deliver a protein to the brain quickly
Potential uses for the study could include repairing spinal cord injuries and a range of other localised injection applications.
whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
whitepaper
Product hub: Uncover spatial biology secrets. Gain disease insights.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
whitepaper
Product hub: CD34+ haematopoietic stem cells: One cell type, multiple viable sources
Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.
whitepaper
Product hub: Light the path to your next neuroscience discovery with a new ultrasensitive NF-L immunoassay
Discover all the ways you can harness ultrasensitive immunoassays to stay at the forefront of neuroscience research.
article
Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
article
Synthetic biology is ready for the therapeutic limelight
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
news
A new strategy to overcome tumour-induced immunosuppression
Researchers have found that blocking key enzymes could boost anti-cancer T cell responses and resistance to immunosuppression.
news
Study reveals novel insights into Crohn’s disease
The findings by Massachusetts General Hospital could point to a potential target to treat Crohn’s disease.
